What Soufflé Therapeutics does

Soufflé Therapeutics is a pre-clinical biotechnology company developing a cell-selective ligand platform for targeted delivery of siRNA-based genetic medicines. The company's core technology engineers cell-specific ligands that ferry siRNA payloads across cell membranes and into precise target cells — including cardiomyocytes and skeletal muscle cells — addressing the long-standing limitation of conventional lipid nanoparticle (LNP) and GalNAc delivery systems that primarily reach the liver. The platform integrates three proprietary capabilities: cell-specific receptor identification, ligand optimization for binding affinity and selectivity, and potent siRNA engineering. Soufflé is designed as a platform replicable across cell types rather than a single-asset company.

The company is headquartered in Watertown, MA, and was founded in 2021 by a scientific team including Robert Langer, Daniel Anderson, Victor Kotelianski, Marino Zerial, and Bradley Pentelute — leaders in drug delivery, RNA therapeutics, and intracellular trafficking. Its initial clinical programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated dilated cardiomyopathy, with first-in-human trials planned to begin in 2026. The company employs 51–100 people and has raised capital and executed collaboration agreements exceeding $3.5 billion in aggregate, including a $200 million financing in January 2025 led by Bessemer Venture Partners.

Soufflé commercializes its pipeline through licensing and co-development partnerships with major pharmaceutical companies rather than direct product sales. Named partners include Bayer (global licensing agreement for a heart-targeted siRNA therapy announced January 2026), AbbVie, Amgen, and Novo Nordisk. Revenue mechanics consist of upfront payments, development and commercial milestones, and future royalties on approved products, consistent with a pre-clinical biotech operating model. The company also benefits from strategic equity investment by Leaps by Bayer and a syndicate of top-tier healthcare and venture investors including Polaris Partners, ARCH Venture Partners, Vida Ventures, and Temasek.

Name

Soufflé Therapeutics

Legal name

Soufflé Therapeutics, Inc.

Website

https://souffletx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Soufflé Therapeutics is a pre-clinical biotech developing cell-specific ligand technology for targeted siRNA delivery beyond the liver, with lead programs in FSHD and PLN cardiomyopathy entering clinical trials in 2026 and a licensing-based business model with partners including Bayer, AbbVie, Amgen, and Novo Nordisk.

Ownership category

akta.pro rank

Product category

RNA-based Genetic Medicines

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• SiRNA therapeutics
• Targeted genetic medicines
• Cell-specific delivery
• RNA-based therapeutics
• Cell-selective ligands

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Licensing and Co-development Agreements: Soufflé develops proprietary siRNA medicines and commercializes them through licensing agreements and co-development partnerships with large pharmaceutical companies, generating revenue through upfront payments, milestone payments, and royalties on approved products.
2. Future Product Sales: As the company advances its pipeline toward clinical trials and potential commercial launch, future revenue may be generated through product sales for its targeted genetic medicines addressing rare genetic diseases and broader metabolic disorders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Soufflé Therapeutics engineers cell-specific ligands to deliver siRNA-based genetic medicines precisely across cell membranes into target cells such as cardiomyocytes and skeletal muscle cells. The company combines proprietary technologies for cell-specific receptor identification, ligand optimization, and potent siRNA engineering to develop therapies addressing rare genetic diseases and broader metabolic disorders. Initial programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and PLN-associated cardiomyopathies, with clinical trials planned to begin in 2026.

Product overview

Soufflé Therapeutics is a biotech company that has developed a unified platform combining proprietary technologies for identification of cell-specific receptors, ligand optimization, and potent siRNA engineering to create cell-selective genetic medicines. The company's core technology enables precise delivery of siRNA-based therapies across cell membranes to specific target cells. Soufflé's initial therapeutic programs include siRNA therapies for Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies targeting PLN gene mutations. A strategic collaboration with Bayer focuses on developing a heart-targeted siRNA therapy for dilated cardiomyopathy. The company is advancing clinical trials in 2026 for its lead programs while building a diversified pre-clinical pipeline across multiple cell and tissue types.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• First clinical trials planned to begin in 2026 for FSHD and PLN-associated cardiomyopathy programs

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• BayercoreStrategic or Co-development Partner · 8 January 2026Bayer and Soufflé Therapeutics announced a strategic collaboration and global licensing agreement to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy. The collaboration leverages Soufflé's cell-selective ligand technology to deliver genetic medicines precisely to cardiomyocytes, addressing challenges in siRNA delivery such as off-target effects and frequent dosing. This partnership marks Bayer's entry into the siRNA therapeutics field and strengthens its cardiovascular portfolio. The collaboration builds on Bayer's prior investment in Soufflé through Leaps by Bayer.
• AbbViemajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with AbbVie as one of its pharma partners. The partnership is part of Soufflé's broader strategy to work with leading pharmaceutical companies dedicated to creating medicines.
• AmgenmajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with Amgen as one of its pharma partners. The partnership is part of Soufflé's strategy to partner with pharmaceutical companies dedicated to creating medicines.
• Novo NordiskmajorStrategic or Co-development PartnerSoufflé Therapeutics has a collaboration relationship with Novo Nordisk as one of its pharma partners, particularly in the area of metabolic disorders.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Novo Nordisk: Global pharmaceutical leader in metabolic disorders and rare disease (with Dicerna siRNA acquisition). Comparable as both a strategic partner of Soufflé in metabolic disease programs and a competitor in cardiometabolic nucleic-acid therapeutics.
• Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved drugs (Spinraza, Tegsedi, Wainua). Directly comparable to Soufflé in nucleic-acid-based gene-silencing therapeutics and is a natural incumbent for genetic cardiometabolic and rare disease indications.
• CRISPR Therapeutics: Clinical/commercial-stage gene editing company with both ex vivo (CASGEVY) and in vivo (cardiovascular) programs. Comparable to Soufflé as an in vivo nucleic-acid medicines company; Daniel Anderson co-founded CRISPR Therapeutics, and several Soufflé leaders (Bogorad, Sun, Bartlett) previously worked there.
• Sarepta Therapeutics: Commercial-stage genetic medicines company focused on Duchenne muscular dystrophy and rare neuromuscular diseases. Comparable to Soufflé in rare muscle disease focus (FSHD) and nucleic-acid/genetic medicine modality; Soufflé's VP Clinical Development (Herb Stevenson) led multiple Sarepta BLA programs including AMONDYS 45.

Direct peers

• Verve Therapeutics: In vivo gene editing company targeting cardiovascular disease (e.g., PCSK9 for familial hypercholesterolemia). Comparable because Soufflé's PLN cardiomyopathy program targets an analogous cardiovascular indication using a different nucleic-acid modality, and Verve's Ellen Rohde and Victoria Bartlett both joined Soufflé's leadership.
• Intellia Therapeutics: In vivo CRISPR/Cas9 gene editing company with LNP-based extrahepatic delivery programs (e.g., NTLA-2002 for HAE). Comparable as a nucleic-acid therapeutics company pursuing extrahepatic in vivo delivery to muscle and other tissues, sharing personnel pedigree (Soufflé's Ellen Rohde pioneered LNP biodistribution at Intellia).
• Arrowhead Pharmaceuticals: Clinical-stage siRNA company with multiple extrahepatic delivery platforms (TRiM) targeting muscle, lung, CNS, and adipose tissue. Closely comparable to Soufflé because both are extending siRNA beyond the liver to tissues like cardiomyocytes and skeletal muscle — the exact cell types Soufflé targets.
• Alnylam Pharmaceuticals: Leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, inclisiran/Leqvio) pioneering GalNAc-conjugate delivery to hepatocytes. Most directly comparable peer given Soufflé's co-founder Victor Kotelianski was Alnylam's founding SVP and co-invented inclisiran, and both compete in siRNA-based genetic medicines.

Emerging players

• Wave Life Sciences: Clinical-stage nucleic-acid therapeutics company developing stereopure oligonucleotides for rare and cardiometabolic diseases (e.g., WVE-006 for alpha-1 antitrypsin deficiency). Comparable as a platform-based oligonucleotide company pursuing extrahepatic tissues including muscle.
• Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies and small molecules for cardiomyopathies and heart failure. Comparable to Soufflé's PLN cardiomyopathy program given overlapping cardiac indication and rare genetic heart disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/souffletherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soufflé Therapeutics